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Abstract Over the past three decades, physicians have used
laser sources for the management of different pain conditions
obtaining controversial results that call for further investiga-
tions. In order to evaluate the pain relieving possibilities of
photobiomodulation therapy (PBMT), we tested two near infra-
red (NIR) laser systems, with different power, against various
kinds of persistent hyperalgesia animal models. In rats, articular
pain was reproduced by the intra-articular injection of sodium
monoiodoacetate (MIA) and complete Freund’s adjuvant
(CFA), while compressive neuropathy was modelled by the
chronic constriction injury of the sciatic nerve (CCI). In MIA
and CFAmodels, (NIR) laser (MLS-Mphi, ASA S.r.l., Vicenza,
Italy) application was started 14 days after injury and was per-
formed once a day for a total of 13 applications. InMIA-treated
animals, the anti-hyperalgesic effect of laser began 5 min after
treatment and vanished after 60 min. The subsequent applica-
tions evoked similar effects. In CFA-treated rats, laser efficacy
started 5 min after treatment and disappeared after 180 min. In
rats that underwent CCI, two treatment protocols with similar
fluence but different power output were tested using a new
experimental device called Multiwave Locked System laser
(MLS-HPP). Treatments began 7 days after injury and were
performed during 3 weeks for a total of 10 applications. Both
protocols reduced mechanical hyperalgesia and hindlimb
weight bearing alterations until 60 min after treatment with a
higher efficacy recorded for the animals treated using the higher
power output. In conclusion, this study supports laser therapy as
a potential treatment for immediate relief of chronic articular or
neuropathic pain.
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Chronic pain is a complex, severe and debilitating condition that
can lead to a considerable reduction in function and quality of life
[1–3]. Indeed, restriction in daily activities, social life and work-
ing assets, sleep disturbances, anxiety and depression is frequent-
ly reported. The burden on society is high and includes consid-
erable healthcare and welfare costs, as well as indirect costs such
as loss of productivity and skills due to absenteeism and early
retirement [4]. Patients may present with different forms of
chronic pain resulting from a number of identifiable causes, in-
cluding pain due to lesion or dysfunction of the nerves, spinal
cord or brain (neuropathic pain) or persistent pain caused by
other non-malignant conditions, such as low-back pain or pain
due to inflammation of various arthritic conditions. For these
reasons, the pain management is often complex and clinically
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challenging, requiring a multimodal treatment approach [5]. For
the pharmacological treatment of the non-neuropathic chronic
pain, opioids are an established standard. However, they are as-
sociated with significant side effects that might influence adher-
ence to treatment or results in treatment discontinuation [6].
Furthermore, the pharmacotherapy for neuropathic pain is disap-
pointing. Patients with neuropathy do not respond to non-
steroidal anti-inflammatory drugs and resistance or insensitivity
to opioids is common. Patients are usually treated with tricyclic
or serotonin and norepinephrine uptake inhibitors, anti-
depressants and anti-convulsants that all have limited efficacy
and undesirable side effects. Indeed, epidemiological surveys
have shown that many patients with neuropathic pain do not
receive appropriate treatment [7, 8]. Thus, the development of
new effective therapies, with lower side effects, is required to
effectively manage neuropathic and chronic pain.
Since many years, laser sources have been applied for the
treatment of various types of pain [9–11]. This kind of
photobiomodulation therapy (PBMT) has become increasing-
ly popular because it is non-invasive, painless and no signif-
icant side effects have been reported. Research on the mech-
anisms underlying the analgesic effects of laser radiation is
carried out since more than 30 years. However, these mecha-
nisms are not yet fully known and the complexity in under-
standing them arises in part by a lack of methodological stan-
dardization of certain studies and by the many different treat-
ment parameters and conditions used.
The purpose of the present study was to evaluate the effec-
tiveness of high power, dual wavelength near infrared (NIR)
laser sources in inducing anti-hypersensitivity effects in vivo
in rat models of pain induced by different causes. Unilateral
sciatic nerve chronic constriction injury (CCI) was adopted as
a rat model of neuropathic pain while intra-articular injections
of monoiodoacetate (MIA) and complete Freud’s adjuvant




For all the experiments described below, male Sprague–Dawley
rats (Envigo, Varese, Italy) weighing approximately 200–250 g
at the beginning of the experimental procedure were used.
Animals were housed in CeSAL (Centro Stabulazione Animali
da Laboratorio, University of Florence) and used 1 week after
their arrival. Four rats were housed per cage (size 26 × 41 cm2),
fedwith standard laboratory diet and tapwater ad libitum, kept at
23 ± 1 °C with a 12-h light/dark cycle and light at 7 a.m. All
animal manipulations were carried out according to the Directive
2010/63/EU of the European parliament and of the European
Union council (22 September 2010) on the protection of animals
used for scientific purposes. The ethical policy of the University
of Florence complies with the Guide for the Care and Use of
LaboratoryAnimals of the USNational Institutes of Health (NIH
Publication No. 85-23, revised 1996; University of Florence as-
surance number: A5278-01). Formal approval to conduct the
experiments described was obtained from the Italian Ministry
of Health (No. 54/2014-B) and from the Animal Subjects
Review Board of the University of Florence. Experiments in-
volving animals have been reported according to ARRIVE
guidelines [12]. All efforts were made to minimize animal suf-
fering and to reduce the number of animals used.
MIA-induced osteoarthritis
Unilateral osteoarthritis was induced by injection of
MIA(Sigma-Aldrich) into the tibiotarsal joint [13, 14]. Rats
were slightly anaesthetized by 2% isoflurane, the left leg skin
was sterilized with 75% ethyl alcohol, and the lateral
malleolus located by palpation; then, a 28-gauge needle was
inserted vertically to penetrate the skin and turned distally for
insertion into the articular cavity at the gap between the
tibiofibular and tarsal bone until a distinct loss of resistance
was felt. Two milligrams of MIA in 25 μL saline was deliv-
ered into the left articular cavity. Control animals received
saline. Laser treatment started 14 days after MIA injection.
CFA-induced inflammatory arthritis
Articular damage was induced by injection of 50 μL CFA
(Sigma-Aldrich) into the tibiotarsal joint [15]. Briefly, the rats
were slightly anaesthetized by 2% isoflurane, the left leg skin
was sterilized with 75% ethyl alcohol, and the lateral malleolus
located by palpation; then, a 28-gauge needle was inserted ver-
tically to penetrate the skin and turned distally for insertion into
the articular cavity at the gap between the tibiofibular and tarsal
bone until a distinct loss of resistance was felt. A volume of
50 μL of CFA was then injected. Control animals received
saline. Laser treatment started 14 days after CFA injection.
CCI-induced peripheral mononeuropathy
Neuropathy was induced according to the procedure described
in Bennett and Xie [16]. Briefly, rats were anaesthetized with
2% isoflurane. Under aseptic conditions, the right (ipsilateral)
common sciatic nerve was exposed at the level of the middle
thigh by blunt dissection. Proximal to the trifurcation, the
nerve was carefully freed from the surrounding connective
tissue, and four chromic catgut ligatures (4–0, Ethicon,
Norderstedt, Germany) were tied loosely around the nerve
with about 1-mm spacing between ligatures. After hemostasis
was confirmed, the incision was closed in layers. The animals
were allowed to recover from surgery and then housed one per
cage with free access to water and standard laboratory chow.
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Another group of rats were subjected to sham surgery in
which the sciatic nerve was only exposed but not ligated.
Laser treatment started 7 days after surgery.
Laser treatments and study design (Fig. 1)
MIA and CFA models were treated with a Multiwave Locked
System laser (MLS-Mphi, ASAS.r.l., Vicenza, Italy). It is a class
IV NIR laser with two synchronized sources (laser diodes). The
first one is a pulsed laser diode, emitting at 905 nm wavelength,
with 25 W peak optical power. The pulse frequency may be
varied in the range 1–2000 Hz. The second laser diode emits
at 808 nm wavelength and may operate in continuous (max
power 1W) or frequenced (repetition rate 1–2000 Hz, 50% duty
cycle) mode. The two laser beams work simultaneously, syn-
chronously and the propagation axes are coincident.
The treatments of the CCI model were performed with a
new MLS-HPP experimental device designed to have the
same kind of sources (laser diodes), emission wavelengths
(808 nm and 905 nm) and synchronized emission mode (con-
tinuous/frequenced and pulsed mode) of the MLS-Mphi laser,
but with a significant increase in terms of power output. In the
experimental device, different power settings can be chosen.
The pulsed source emits at 905 nm wavelength, with peak
power from 140 W to 1 kW ± 20%. The pulse frequency may
be varied in the range 1–2000 Hz (1–40 Hz for maximum
power). The continuous source emits at 808 nm wavelength
and may operate in continuous (max power 6 W ± 20%) or
frequenced (repetition rate 1–2000Hz, 50% duty cycle) mode.
Also, the sources of the MLS-HPP experimental device work




Ia. Control (n = 5). Animals injected with saline without
MIA
Ib. MIA (n = 5), laser-untreated animals;
Ic. MIA—Laser-treated group (n = 5), animals exposed to
laser radiation. The treatment started 14 days after MIA
injection and was performed once a day for 13 days dur-
ing 3 weeks (days 1–5; 8–12; 15–17). It consisted in
irradiation of two points, one located on the medial side
of the patella and the other on lateral side. Each point was
treated for 8 s with the following laser parameters: 30 Hz,
25% int (mean power 125 mW), peak power905 25 W,
0.32 J/cm2, 1 J/point.
II. CFA group
IIa. Control (n = 5). Animals injected with saline instead of
CFA
IIb. CFA (n = 5), laser-untreated animals;
IIc. CFA—Laser-treated group (n = 5), animals exposed to
laser radiation. The treatment started 14 days after CFA
injection and was performed once a day for 13 days
during 3 weeks (days 1–5; 8–12; 15–17). It consisted
in irradiation of two points, as described in Ic. Each
point was treated for 4 s with the following laser param-
eters: 30 Hz (mean power 125 mW), peak power905
25 W, 25% int, 0.16 J/cm2, 0.5 J/point.
III. CCI group
IIIa. Sham (n = 5). Animal subjected to sham surgery in
which the sciatic nerve was only exposed but not
ligated.
IIIb. CCI (n = 5), laser-untreated animals;
IIIc. CCI—Laser-treated group 1 (n = 5), animals exposed to
laser radiation. The treatment was started 7 days after
surgery and was performed once a day for 10 days dur-
ing 3 weeks (days 1–3; 6–10; 13–14). It consisted in
irradiation of two points, one located directly on sciatic
nerve ligation and the other on lateral side of the calca-
neus (paw joint), followed by a scan of the limb per-
formed by moving continuously the handpiece along
the limb of the animal. Points were treated for 5 s with
the following laser parameters: 30 Hz, 20% int (mean
power 680 mW), peak power905140W, 1.08 J/cm
2,
3.4 J/point. Scan was performed for 124 s with the
following parameters: 700 Hz, 50% int (mean power
1700mW), peak power905 140W, 5.28 J/cm
2, 211.13 J.
IIId. CCI—Laser-treated group 2 (n = 5), animals exposed to
laser radiation. The treatment was started 7 days after
surgery and was performed once a day for 10 days dur-
ing 3 weeks (days 1–3; 6–10; 13–14) and consisted in
irradiation of two points, followed by a scan of the limb
(see IIIc). Points were treated for 3 s with the following
laser parameters: 30Hz, 20% int (mean power 980mW),
peak power905 1 kW ± 20%, 0.94 J/cm
2, 2.96 J/point.
Scan was performed for 108 s with the following param-
eters: 40 Hz, 50% int (mean power 1940 mW), peak
power905 1 kW ± 20%, 5.24 J/cm
2, 209.8 J.
Paw pressure test
The nociceptive threshold in the rat was determined with an
analgesimeter (Ugo Basile, Varese, Italy) according to the
method described by Leighton et al. [17]. Briefly, a constantly
increasing pressure was applied to a small area of the dorsal
surface of the hind paw using a blunt conical mechanical
probe. Mechanical pressure was increased until vocalization
or a withdrawal reflex occurred while rats were lightly re-
strained. Vocalization or withdrawal reflex thresholds were
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expressed in grams. These limits assured a more precise de-
termination of mechanical withdrawal threshold in experi-
ments aimed to determine the effect of treatments. An arbi-
trary cut-off value of 100 g was adopted. For MIA and CFA,
laser treatments were started 14 days after injury and Paw
pressure test was performed on days 1–5; 8–12; and 15–
17 at 0, 5, 30, 60 and 180 min after laser application. For
CCI, laser treatments started 7 days after injury and Paw pres-
sure test was performed on days 1–3; 6–10; and 13–14 at 0, 5,
30, 60 and 180 min after laser application. The data were
collected by an observer who was blinded to the protocol.
Incapacitance test
Weight bearing changes were measured using an incapacitance
apparatus (Linton Instrumentation, UK) detecting changes in
postural equilibrium after a hindlimb injury [18]. Rats were
trained to stand on their hind paws in a box with an inclined
plane (65° from horizontal). This box was placed above the
incapacitance apparatus. This allowed us to independently mea-
sure the weight that the animal applied on each hindlimb. The
value considered for each animal was the mean of five consec-
utive measurements. In the absence of hindlimb injury, rats ap-
plied an equal weight on both hindlimbs, indicating a postural
equilibrium, whereas an unequal distribution of the weight on
hindlimbs indicated a monolateral decreased pain threshold.
Data are expressed as the difference between the weight applied
on the limb contralateral to the injury and the weight applied on
the ipsilateral one. This behaviouralmeasurementwas performed
only on CCI rats on days 1–3; 6–10; 13–14 at 0 and 60min after
laser application. Blind experiments were performed.
Statistical analyses
Behavioural measurements were performed on five rats for
each treatment. Measurements were taken in duplicate at least
1 min apart; the responses of both left and right paws were
measured. Results were expressed as mean (sem) with one-
way analysis of variance (ANOVA). A Bonferroni’s signifi-
cant difference procedure was used as a post hoc comparison.
Data were analysed using the BOrigin 9.0^ software
(OriginLab, Northampton, MA, USA). Differences were con-
sidered significant at a P < 0.05.
Results
MIA-induced osteoarthritis
The pain reliever effect of repeated laser treatments was
evaluated on MIA-induced osteoarthritis model in the rat
(in Fig. 2).
Fig. 1 Laser treatment protocols with time schedule and parameters used
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Laser application started 2 weeks after MIA intra-articular
injection (day-14), when the tolerance to a suprathreshold
stimulation was reduced to 45.0 ± 1.0 g in comparison to
control animals (62.5 ± 1.4 g) (day 1, 0 min; Fig. 2) and was
performed once a day, for 13 days during 3 weeks (days 1–5;
8–12; 15–17), using an MLS-Mphi laser. On the same days,
the nociceptive threshold was measured by Paw pressure test
before (black curve) and after (5 min, blue curve; 30 min, pink
curve; 60 min, green curve; and 180 min, wine curve) treat-
ment (Fig. 2). The first laser application increased of 24% the
weight tolerated on the posterior paw 5 min after treatment.
The anti-hypersensitivity effect remained significant after
30 min and vanished at 60 min (53.8 ± 2.2 and 43.3 ± 0.8 g,
respectively). The pain reliever effect was no longer recorded
after 24 h (day 2, before treatment), but new treatments (per-
formed on days 2–5) were able to induce effects comparable
to that obtained on day 1. The four laser applications carried
out from days 8 to 11 were less effective to reduce the noci-
ceptive alteration induced by MIA than those performed pre-
viously. On the contrary, the following administrations (days
12, 15–17) increased the pain threshold in a similarly (similar)
to the first ones (days 1–5). The nociceptive threshold of the
contralateral paw did not change during the entire duration of
the experiment (data not shown). Also, the nociceptive thresh-
old of the laser-untreated MIA group did not change signifi-
cantly during the entire experiment, as shown in able 1.
CFA-induced inflammatory arthritis
In the CFA model, we evaluated the antinociceptive effect of
repeatedMLS-Mphi laser treatments in articular inflammatory
damage resembling human rheumatoid arthritis (Fig. 3). In the
same days of laser treatment, the hypersensitivity to a mechan-
ical noxious stimulus (Paw pressure test) was measured before
(black curve) and after (5 min, blue curve; 30 min, pink curve;
60 min, green curve and 180 min, wine curve) treatment (Fig.
3). On day 1, before laser application, rats underwent to CFA
intra-articular injection tolerated a weight of 43.0 ± 0.8 g on
the ipsilateral paw with respect to 62.5 ± 1.4 g of the control
group. Laser treatment reverted CFA-induced hypersensitivity
5 min after administration (64.2 ± 1.5 g), the effect was still
significant at 30 (55.8 ± 1.7 g) and 60 min (50.0 ± 0.3 g) and
disappeared at 180 (44.2 ± 0.8 g). Although the pain reliever
effect of laser was no longer recorded after 24 h (day 2, before
treatment), a new laser application was able to reach a signif-
icant anti-hypersensitivity effect (at 5 and 30 min, 58.5 ± 0.8
and 55.3 ± 1.5 g, respectively) even if with a lower efficacy to
that obtained on day 1. Similar effects were observed the fol-
lowing days (3–5, 8–12 and 15–17; Fig. 3). The nociceptive
threshold of the contralateral paw did not changed during the
entire duration of the experiment as well as the nociceptive
threshold of the laser-untreated CFA group, shown in able 2.
CCI-induced peripheral mononeuropathy
After these results obtained irradiating directly the damage
points (articular joint) in MIA and CFA models and following
a preliminary study on the effect of a similar laser treatment in
CCI-induced mononeuropathy, we carried out further experi-
ments using a new MLS-HPP experimental device in order to
evaluate its effectiveness in relieving CCI-induced
mononeuropathy and comparing two setup with similar fluence
but different output power. A first group of rats (IIIc) was treat-
ed using the setup characterized by lower power. Laser appli-
cation started 1 week after surgery and was performed once a
day (Fig. 4). The evaluation of hypersensitivity was carried out
before (black curve) and after (5 min, blue curve; 30 min, pink
curve; 60 min, green curve; and 180min, wine curve) treatment
on the ipsilateral (operated) paw. Sciatic nerve ligation reduced
the pain response to a mechanical noxious stimulus (Paw
pressure test; Fig. 4) from a value of 62.8 ± 0.9 g in the sham
animals to 46.3 ± 0.7 g (day 1, 0 min), and this condition
lingered until the end of the experiment (day 14). Laser appli-
cation significantly increased the paw threshold at 5 and 30 min
after treatment (53.8 ± 1.3 and 51.9 ± 1.2 g, respectively). The
anti-hypersensitivity effect was no longer recorded after 24 h
(day 2, before treatment) but a new laser treatment evoked an
effect comparable to that obtained in the previous day.
Moreover, the effect was statistically significant after 60 min
and vanished at 180 min. Similar results were recorded during
the following days of treatment (Fig. 4). Unilateral pain as CCI
was also able to induce hindlimb weight bearing alterations
(Incapacitance test; Fig. 4). The difference between the weight
burdened on the contralateral and the ipsilateral paw was sig-
nificantly increased in CCI rats (on day 1, 14 days after surgery)
before laser treatment (58.2 ± 3.3 g) with respect to the sham
group (5.2 ± 3.6 g). Laser administration reduced 50% of this
gap at 60 min. The relief was no longer showed 24 h later (Fig.
4). This trend was confirmed during the following administra-
tions (days 2–3, 6–9, and 13–14).
The other group of rats (IIId) was treated with a similar
protocol, but with the setup delivering higher power (Fig. 5).
On day 1 (7 days after injury), laser reverted the hypersen-
sitivity induced by the sciatic nerve ligation at 5 min
(63.8 ± 0.7 vs 45.0 ± 1.0 g recorded on min 0), the effect
decreased at 30 min (57.5 ± 1.0 g) and disappeared at
60 min (46.3 ± 0.7 g). During the following days of treat-
ments, laser efficacy was effective also at 60 min, vanishing
3 h later (Fig. 5).
As previously described, laser application was able to re-
duce of 50% the hindlimb weight bearing alteration induced
by CCI at 60 min for the entire experiment (Fig. 5). able 3 lists
the nociceptive threshold data for the CCI group (no laser
treatment) measured by Paw pressure test during the entire
experiment (Table 3): non-significant changes were monitored
in the course of the experiment.
Lasers Med Sci (2017) 32:1835–1846 1839
Discussion
The present results highlight the pain reliever effect of laser
treatments in two rat models of articular pain (MIA and CFA)
and in a rat model of CCI-induced mononeuropathy.
Rheumatoid arthritis (RA) and osteoarthritis (OA) are joint
diseases characterized by different pathophysiological mech-
anisms, but displaying common clinical characteristics, such
as joint pain, functional impairment and structural damage that
are hallmarked by bone erosions in RA and osteophytes in
OA. Moreover, both diseases display joint space narrowing,
reflecting cartilage loss [19].
OA is the most common subtype and it is particularly wide-
spread among adults over age 60 years and those who are
overweight or obese [20]. RA is an autoimmune disease in-
volving extreme joint tissue inflammation [21]; it is far less
pervasive and affects 1% of adults, typically with an onset at
around age 40 years [22].
MIA-induced osteoarthritis in experimental animals is the
best model to describe the effect of treatments on this
Table 1 Response to a
mechanical noxious stimulus of
MIA-treated animals, Paw pres-
sure test
Weight (g)
Days of laser treatment 0 min 5 min 30 min 60 min 180 min
1 45.0 ± 1.2 44.8 ± 0.9 46.3 ± 1.0 45.3 ± 0.5 42.7 ± 2.2
2 43.9 ± 2.4 45.0 ± 0.7 44.6 ± 1.3 43.5 ± 1.2 46.7 ± 0.3
3 45.7 ± 0.7 45.2 ± 1.6 43.1 ± 2.6 43.5 ± 0.4 45.8 ± 0.6
4 44.8 ± 0.4 42.7 ± 2.5 44.8 ± 0.8 44.7 ± 2.0 44.6 ± 1.4
5 45.6 ± 1.3 44.6 ± 1.8 43.6 ± 1.2 45.6 ± 2.0 45.0 ± 0.9
8 43.6 ± 1.2 44.1 ± 0.7 45.7 ± 1.1 44.2 ± 0.8 44.0 ± 1.2
9 43.6 ± 0.8 43.7 ± 1.2 44.6 ± 1.4 42.8 ± 2.1 44.6 ± 1.4
10 44.1 ± 0.7 44.3 ± 0.7 42.8 ± 1.6 43.1 ± 0.9 44.5 ± 0.6
11 45.6 ± 0.4 43.6 ± 1.2 44.6 ± 0.9 43.9 ± 2.1 44.1 ± 1.5
12 43.8 ± 0.8 42.8 ± 2.4 43.8 ± 1.1 44.5 ± 0.9 43.8 ± 1.2
15 44.6 ± 1.0 43.8 ± 2.0 46.7 ± 0.5 44.6 ± 1.3 44.1 ± 0.8
16 45.7 ± 3.0 45.6 ± 1.0 43.7 ± 1.6 43.6 ± 0.8 45.8 ± 0.9
17 46.2 ± 0.9 44.7 ± 0.5 46.7 ± 0.7 44.5 ± 1.4 43.7 ± 1.3
Paw pressure test performed on MIA-treated animals. The response to a mechanical noxious stimulus was
evaluated at the same time points of MIA-laser treated group. Behavioural measurements started 14 days after
MIA intra-articular injection. Each value represents the mean ± sem of five rats
Fig. 2 Osteoarthritis model
induced by MIA. Intra-articular
injection of MIAwas performed
2 weeks before the beginning of
the test (day-14). Laser treatment
(30 Hz, 25% int, 8 s, 0.32 J/cm2,
1 J/point, two treated points) was
applied on days 1–5; 8–12; and
15–17. The response to a noxious
mechanical stimulus was mea-
sured by Paw pressure test.
Behavioural measurements were
conducted before (0 min, black
curve) and after (5 min, blue
curve; 30min, pink curve; 60min,
green curve and 180 min, wine
curve) laser treatment. Each value
represents the mean ± sem of five
rats per group. *P < 0.05 and
**P < 0.01 vs the values at 0 min
on the same day
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pathology because it mimics severe and acute OA pain that is
similar with humans [23, 24]. The histological and morpho-
logical alterations of the cartilage are associated with a persis-
tent inflammatory pain which, starting from the 14th day after
MIA injection, possesses a neuropathic component [14, 25].
The results of the experiments showed that daily laser treat-
ments, consisting in the irradiation of two points, were able to
increase the pain threshold of the animals from 5 to 30 min
after laser application. Laser treatment started 14 days after
MIA injection, when articular damages were established and
rats showed a high degree of hypersensitivity against mechan-
ical stimuli (Paw pressure test). Laser efficacy exhibited the
same anti-hypersensitivity profile during the first week of
treatment (days 1–5), while it decreased during the second
week (days 8–12) to newly upturn on days 15–17. A similar
protocol, with variation of time exposure and, consequently,
dose administered, was used in a rat model of CFA-induced
rheumatoid arthritis.
In the CFA arthritis model, the animal develops chronic
swelling and pain in and around the joints with a release of
Table 2 Response to a
mechanical noxious stimulus of
CFA animals, Paw pressure test
Weight (g)
Days of laser treatment 0 min 5 min 30 min 60 min 180 min
1 43.1 ± 1.3 42.4 ± 1.5 43.9 ± 0.8 42.8 ± 1.4 44.9 ± 0.7
2 44.0 ± 0.7 43.7 ± 0.9 45.1 ± 0.9 44.4 ± 0.8 44.7 ± 1.4
3 44.5 ± 1.7 42.8 ± 2.0 44.3 ± 1.6 44.8 ± 0.7 45.1 ± 1.3
4 45.8 ± 0.5 44.7 ± 1.0 45.1 ± 0.3 45.3 ± 0.6 44.8 ± 0.4
5 45.1 ± 0.7 43.7 ± 0.8 43.4 ± 0.9 45.6 ± 1.4 44.8 ± 1.1
8 45.0 ± 1.0 45.7 ± 0.4 43.9 ± 2.1 44.6 ± 1.3 45.8 ± 0.5
9 46.1 ± 0.7 45.4 ± 1.0 45.9 ± 0.3 45.7 ± 1.3 46.4 ± 0.5
10 46.5 ± 0.4 45.8 ± 2.0 46.6 ± 0.6 44.2 ± 2.1 45.8 ± 1.2
11 45.6 ± 2.1 46.1 ± 0.9 45.4 ± 1.0 46.3 ± 0.9 44.9 ± 2.5
12 46.1 ± 0.7 46.2 ± 0.3 45.1 ± 0.5 46.1 ± 0.4 45.4 ± 0.5
15 45.1 ± 1.2 45.9 ± 0.9 45.1 ± 1.2 46.3 ± 0.8 45.6 ± 0.9
16 46.1 ± 0.9 46.2 ± 0.4 45.1 ± 2.4 46.1 ± 0.9 46.7 ± 0.5
17 45.2 ± 1.4 45.9 ± 0.7 45.1 ± 1.1 46.3 ± 0.6 45.2 ± 0.3
Paw pressure test performed on CFA-treated animals. The response to a mechanical noxious stimulus was
evaluated at the same time points of CFA-laser treated group. Behavioural measurements started 14 days after
CFA intra-articular injection. Each value represents the mean ± sem of five rats
Fig. 3 Rheumatoid arthritis
model induced by CFA. Intra-
articular injection of CFAwas
performed 2 weeks before the
beginning of the test (day-14).
Laser treatment (30 Hz, 25% int,
4 s, 0.16 J/cm2, 0.5 J/point, two
treated points) was applied on
days 1–5; 8–12; and 15–17. The
response to a noxious mechanical
stimulus was measured by Paw
pressure test. Behavioural mea-
surements were conducted before
(0 min, black curve) and after
(5 min, blue curve; 30 min, pink
curve; 60 min, green curve and
180 min, wine curve) laser treat-
ment. Each value represents the
mean ± sem of five rats per group.
*P < 0.05 and **P < 0.01 vs the
values at 0 min on the same day
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proinflammatory cytokines, which causes cartilage erosion
and bone destruction. In this study, rats showed a progressive
development of hypersensitivity to mechanical noxious stim-
ulus (Paw pressure test) that peaked 14 days after CFA
injection. At this time point, laser treatment started and was
able to reduce the hypersensitivity from 5 to 60 min after
treatment. In this model of articular damage, the efficacy of
laser was higher during the first week of application and
Fig. 4 a Monolateral neuropathy model induced by CCI. Sciatic nerve
ligation was performed 7 days before the beginning of the test (day-7).
Laser treatment [30 Hz, 20% int (mean power 680 mW), peak power905
140 W, 5 s, 1.08 J/cm2, 3.4 J/point, two treated points; scan 700 Hz, 50%
int (mean power 1700 mW), peak power905 140 W, 124 s, 5.28 J/cm
2,
211.13 J tot] was applied on days 1–3; 6–10; and 13–14. The response to
a noxious mechanical stimulus was measured by Paw pressure test.
Behavioural measurements were conducted before (0 min, black curve)
and after (5 min, blue curve; 30 min, pink curve; 60 min, green curve and
180 min, wine curve) laser treatment. Each value represents the
mean ± sem of five rats per group. *P < 0.05 and **P < 0.01 vs the
values at 0 min on the same day. b Monolateral neuropathy model
induced by CCI. Sciatic nerve ligation was performed 7 days before the
beginning of the test (day-7). Laser treatment [30 Hz, 20% int (mean
power 680 mW), peak power905 140 W, 5 s, 1.08 J/cm
2, 3.4 J/point,
two treated points; scan 700 Hz, 50% int (mean power 1700 mW), peak
power905 140W, 124 s, 5.28 J/cm
2, 211.13 J tot] was applied on days 1–3;
6–10; and 13–14. The hindlimb weight bearing alteration was measured
by Incapacitance test. Behavioural measurements were conducted before
and 60 min after laser treatment. Each value represents the mean ± sem of
five rats per group. **P < 0.01 vs sham group; °°P < 0.01 vs CCI + laser
at 0 min on the same day
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slightly decreased during the second and the third week. In
both MIA- and CFA-treated rats, the anti-hypersensitivity ef-
fect of laser disappeared 24 h after treatment suggesting a
symptomatic pain relief profile and this effect could be due
to a temporary reduction of proinflammatory cytokines and,
subsequently, to a decrease of inflammation. A previous study,
carried out on a rat model of acute inflammation, demonstrat-
ed that 650 nm wavelength laser radiation strongly reduced
TNFα expression [26]. In a study subsequently performed on
hemorrhagic lesions induced by immune complex in rat lungs,
Fig. 5 a Monolateral neuropathy model induced by CCI. Sciatic nerve
ligation was performed 7 days before the beginning of the test (day-7).
Laser treatment [30 Hz, 20% int (mean power 980 mW), peak power905
1 kW ± 20%, 3 s, 0.94 J/cm2, 2.96 J/point, two treated points; scan 40 Hz,
50% int (mean power 1940 mW), peak power905 1 kW ± 20%, 108 s,
5.24 J/cm2, 209.8 J] was applied on days 1–3; 6–10; and 13–14. The
response to a noxious mechanical stimulus was measured by Paw
pressure test. Behavioural measurements were conducted before (0 min,
black curve) and after (5 min, blue curve; 30 min, pink curve; 60 min,
green curve; and 180 min, wine curve) laser treatment. Each value
represents the mean ± sem of five rats per group. *P < 0.05 and
**P < 0.01 vs the values at 0 min on the same day. b. Monolateral
neuropathy model induced by CCI. Sciatic nerve ligation was
performed 7 days before the beginning of the test (day-7). Laser
treatment [30 Hz, 20% int (mean power 980 mW), peak power905
1 kW ± 20%, 3 s, 0.94 J/cm2, 2.96 J/point, two treated points; scan
40 Hz, 50% int (mean power 1940 mW), peak power905 1 kW ± 20%,
108 s, 5.24 J/cm2, 209.8 J] was applied on days 1–3; 6–10; and 13–14.
The hindlimb weight bearing alteration was measured by Incapacitance
test. Behavioural measurements were conducted before and 60 min after
laser treatment. Each value represents the mean ± sem of five rats per
group. **P < 0.01 vs sham group; °P < 0.05 and °°P < 0.01 vs CCI + laser
at 0 min on the same day
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the same authors observed that the anti-inflammatory effect
elicited by 650 nm wavelength laser radiation was similar to
that of pharmacological agents such as celecoxib and dexa-
methasone [26]. A significant reduction in PGE2 was also
reported in a clinical study performed on patients with bilat-
eral Achilles tendonitis [27]. Substances with hyperalgesic
action, such as prostaglandins, are able to reduce the excita-
tion threshold of nociceptive receptors. Therefore, the inhi-
bition of their release can lead to pain reduction. This mech-
anism supports the hypothesis that laser application with
suitable treatment parameters can improve pain symptoms
by modulat ing inf lammation and i ts mediators .
Nevertheless, the reduction of proinflammatory cytokines
may not be the only mechanism of action involved.
Another mechanism that could be involved in laser-
mediated analgesia is based on opioid response and inhibi-
tion of neuronal transmission. It is well known that opioid
peptides can inhibit sympathetic nervous system outflow,
thus exerting analgesic action. Some studies demonstrated
that laser radiation induces an increase in concentration of
some opioids, concurrently with pain reduction reported by
patients. Walker et al. [28], who first investigated this aspect,
reported that laser radiation decreased pain and increased the
urinary excretion of serotonin and its degradation products,
such as 5-hydroxy indole acetic acid (5-HIAA). In a similar
study, using 904 nm wavelength radiation to treat patients
with chronic orofacial pain, Hansen et al.[29] observed that,
although on average pain reduction was not statistically sig-
nificant, there was an increase in the urinary excretion of 5-
HIAA in patients with reduced pain. A few years later,
Laakso et al. [30] observed decreased pain and increased
levels of adrenocorticotropic hormone and β-endorphin fol-
lowing laser irradiation of myofascial trigger points in pa-
tients affected by neck and shoulder pain.
Direct inhibition of neural activity has also been identified
as a plausible mechanism of laser-mediated pain-relieving ef-
fect. In in vivo studies, it has been shown that laser irradiation
can partially or totally inhibit nerve conduction and can affect
conduction velocity and action potential amplitude [31].
Studies on rat models showed that laser radiation inhibits Aδ
and C fibre transmission of nociceptive stimuli induced by
cold/heat, chemicals and proinflammatory substances [32,
33]. Later studies demonstrated that laser irradiation can in-
duce suppression of bradykinin evoked action potentials [34]
and downregulation of kinin receptors [35, 36]. Moreover, a
recent work demonstrated that laser treatment reduced me-
chanical hypersensitivity in a model of neuropathic pain in-
duced by spinal nerve injury through the modulation of
macrophage/microglial cells activation [37].
In this study, we tested also the efficacy of a new MLS-
HPP experimental device and compared two setups allowing
treatments with similar dose but different power output in a
model of mononeuropathy. This model evoked a pain syn-
drome characterized by increased response to a suprathreshold
stimulation that begins about 3 days after nerve injury and
reaches a plateau that lasts between 7 and 30 days [38]. In
our experiments, we started the laser treatments 1 week after
injury. Results highlighted the effectiveness of both protocols
in alleviating pain, but a higher efficacy of the treatment per-
formed with the higher power output was evident since the
first day of application (complete reversion of hyperalgesia).
Instead, no difference was recorded in the ability to reduce
postural unbalance. As previously described for the experi-
ments on MIA and CFA, the anti-hypersensitivity effect of
laser applications was no longer recorded 24 h after treatment,
suggesting a symptomatic pain relief. Conversely, the
antinociceptive effect of laser remained stable during days
without a loss of efficacy on the second and third week of
Table 3 Response to a
mechanical noxious stimulus of
CCI animals, Paw pressure test
Weight (g)
Days of laser treatment 0 min 5 min 30 min 60 min 180 min
1 45.3 ± 0.5 44.5 ± 1.1 45.4 ± 0.5 44.9 ± 1.2 45.1 ± 1.2
2 45.1 ± 1.2 45.6 ± 0.9 44.8 ± 1.5 45.6 ± 0.4 46.3 ± 1.0
3 46.1 ± 0.7 46.2 ± 1.0 46.4 ± 0.8 45.4 ± 1.1 46.4 ± 0.9
4 45.8 ± 1.2 46.3 ± 0.5 46.0 ± 0.8 45.8 ± 1.2 46.1 ± 1.0
5 46.3 ± 0.7 46.4 ± 0.9 45.4 ± 1.2 46.8 ± 1.4 46.4 ± 1.6
8 46.8 ± 0.4 46.1 ± 0.8 45.4 ± 2.3 46.0 ± 1.7 45.3 ± 1.2
9 45.4 ± 1.5 46.2 ± 0.3 45.4 ± 0.8 46.8 ± 0.5 46.1 ± 0.7
10 47.0 ± 0.5 46.3 ± 1.2 46.6 ± 0.7 46.7 ± 0.2 45.8 ± 1.2
11 46.2 ± 1.8 45.3 ± 0.4 46.7 ± 1.1 44.9 ± 1.2 46.7 ± 0.7
12 45.1 ± 0.8 46.8 ± 0.7 46.7 ± 0.9 45.3 ± 1.3 46.4 ± 1.5
Paw pressure test performed on CCI-treated animals. The response to a mechanical noxious stimulus was eval-
uated at the same time points of CCI-laser treated group. Behavioural measurements started 7 days after CCI intra-
articular injection. Each value represents the mean ± sem of five rats
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treatment with both setups. This outcome could be due to the
scan of the limb, administered in addition to the treatment on
fixed points, which was not performed on arthritic rats, and/or
to the higher power characterizing the new MLS-HPP exper-
imental device. The efficacy of NIR laser treatment on rats
underwent to CCI was already showed in our previous exper-
iments. We demonstrated that the application of high power
NIR laser (MLS-Mphi) statistically increased the pain thresh-
old of the neuropathic animals [39]. These results are in agree-
ment with a recent work showing that laser application (660
and 980 nm wavelength) increased thermal and mechanical
threshold in the samemodel of CCI-induced neuropathy in the
rat [40]. In conclusion, the results of this study demonstrate
the efficacy of PBMT by high-power NIR laser in different
models of articular pain and in a model of mononeuropathy in
the rat. In MIA and CFA-treated animals, the anti-
hypersensitivity effect was higher during the first week of
treatment in comparison to the effect highlighted on the sec-
ond and third week. On CCI-treated rats, the efficacy of laser
application, performed using a new MLS-HPP experimental
device, remained stable throughout the experiment. Moreover,
in this model of mononeuropathy, the higher efficacy of the
setup delivering higher power output was highlighted. These
results lead to suggest a clinical application of these treatment
protocols in patients with arthritis and neuropathic pain.
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